The National Heart, Lung, and Blood Institute (NHLBI) has announced that it is committing $12M (£9.5M) in funding to support its Trans Omics for Precision Medicine (TOPMed) programme. The money will be used to enhance data analysis across the next three years.

TOPMed was launched as part of the National Institutes of Health’s Precision Medicine Initiative to build a repository of sequencing, omic, and clinical data from diverse patient populations. The programme involves using high-throughput omics technology to investigate the molecular abnormalities and signatures of heart, lung, blood, and sleep (HLBS) disorders.

“Having produced an unprecedented volume of high-throughput data, TOPMed now seeks to turn its attention to effectively leveraging this resource through novel systems biology analyses to uncover disease pathobiology,” the NHLBI said. “Although lower costs and technological improvements in sequencing technology have vastly expanded our ability to generate large volumes of omics data, the ability to analyse such large datasets to extract biologically meaningful insights from them remains challenging. Thus, advanced analyses that incorporate genotype and phenotype datasets from thousands to tens of thousands of individuals are required to move TOPMed to the next phase of discovery.”

The NHLBI has announced that they will be donating $12M to the project: $3M in 2018, $6M in 2019, and a final $3M in 2020 (fiscal years). The money will fund up to 12 research projects focused on exploring the molecular mechanisms of HLBS disorders using data generated by the TOPMed programme.

If you’re interested in learning more about the funding opportunity, further details can be found here.